title: Cell-penetrating peptides-the Swiss Army knife of cancer vaccines.
abstract: Therapeutic cancer vaccination is an attractive treatment modality for cancer, but with limitations using existing whole-cell, peptide, or protein vaccines. We propose that a cell-penetrating peptide (CPP)-based vaccine delivering multi-epitopic antigens into antigen-presenting cells (APCs) offers great potential to induce an integrated antitumor immune response and robust, sustained therapeutic effect.
authors.affiliation: Centre of Oncology, Geneva University Hospitals and University of Geneva , Geneva, Switzerland.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Walker
authors.affiliation: Amal Therapeutics S.A. , Geneva, Switzerland.
authors.forename: Elodie
authors.initials: E
authors.lastname: Belnoue
authors.affiliation: Centre of Oncology, Geneva University Hospitals and University of Geneva , Geneva, Switzerland.
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Dietrich
authors.affiliation: Amal Therapeutics S.A. , Geneva, Switzerland.
authors.forename: Madiha
authors.initials: M
authors.lastname: Derouazi
keywords: CD4+ T cells; CD8+ T cells; Cell-penetrating peptide; therapeutic cancer vaccines